Home » Newsletters » BioWorld Science

BioWorld Science

May 25, 2010

View Archived Issues

AGN-203818 useful to reduce hypersensitivity in heartburn and IBS patients

Acute rejection rates similar with CP-690550 and ciclosporin in renal transplant patients

Pfizer identifies new fatty-acid amide hydrolase inhibitors

Ranolazine exhibits antifibrillatory activity during severe coronary stenosis

Phase II data in cystic fibrosis disclosed on TR-02

Clinical safety and pharmacokinetic data of inhaled liposomal ciprofloxacin reported

Comparable safety/efficacy/tolerability of ilaprazole and esomeprazole in duodenal ulcer

Increased IGFBP-7 expression reduces breast cancer growth

Lundbeck reports highlights of first quarter 2010

NeuroTherapeutics closes series B financing to advance pipeline

Vagifem 10-mcg tablets replace 25-mcg formulation for atrophic vaginitis

Anadys reports on phase II combination trial of ANA-598

AndroScience and Orient Europharma collaborate on topical acne therapy

Bayer Schering Pharma claims new MEK 1 inhibitors

Janssen describes new serotonin receptor ligands

Ligand acquires milestone and royalty interest in MEDI-528 for asthma

New mGlu5 receptor antagonists claimed by GlaxoSmithKline

Sorrento Therapeutics receives NIH grant for innovative MRSA infection program

Grifols acquires Pharmalink's post-polio syndrome drug development project

NORD awards Shire for developing VPRIV in Gaucher's disease

Elagolix meets all efficacy endpoints in phase II trial in endometriosis

FDA extends review period of FTY-720 in relapsing MS

New data on coadministration of Intuniv and stimulants in ADHD

Enrollment complete in phase II brentuximab vedotin trial in ALCL

Phase III data reported on clobazam in Lennox-Gastaut syndrome

Intercell honored for developing IC-51 Japanese encephalitis vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...